Physician profile
Daniel R More
NPI 1306844279
$4,259.55
in general payments reported to CMS, 2019-2025
20 companies · $1,020 in 2025
The $1,020 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,760 · 2023: $476 · 2024: $1,004 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,499.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,784.93 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $742.62 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $337.21 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $186.44 | 2022-2025 | Takhzyro, Cuvitru, Eohilia |
| Astrazeneca Pharmaceuticals LP | $177.86 | 2022-2025 | Fasenra, Tezspire, Airsupra |
| Csl Behring | $158.34 | 2023-2025 | Hizentra, Haegarda |
| Pharming Healthcare, INC. | $131.62 | 2024-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $131.57 | 2022-2025 | |
| Blueprint Medicines Corporation | $105.25 | 2023-2025 | Ayvakit |
| Genentech USA, INC. | $102.94 | 2024-2025 | Xolair |
| Amgen INC. | $88.47 | 2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $55.24 | 2025 | Neffy |
| Octapharma USA, INC. | $52.46 | 2024-2025 | Cutaquig |
| Merck Sharp & Dohme LLC | $51.14 | 2023 | |
| Lilly USA, LLC | $49.29 | 2025 | Ebglyss, Taltz |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $24.50 | 2023 | |
| Ionis Pharmaceuticals, INC. | $22.56 | 2025 | |
| Galderma Laboratories, L.P. | $20.76 | 2025 | Nemluvio |
| Alk-Abello, INC | $19.77 | 2025 | Ragwitek, Odactra, Grastek |
| Grifols USA, LLC | $16.58 | 2025 | Xembify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel More listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.